Table 4.
Clinical characteristics of renal angiomyolipoma by gender.
| Characteristics | Female N = 1,152 | MaleN = 1,059 | Odds ratio (95% CI) | P-value |
|---|---|---|---|---|
| Past history of renal angiomyolipoma | 615 (53.4) | 447 (42.2) | 1.6 (1.3, 1.9) | <0.0001 |
| Median (range) age at angiomyolipoma diagnosis, years | 14 (<1–63) | 11 (<1–67) | – | 0.9891 |
| Renal angiomyolipoma ongoing during the studya | 590 (95.9) | 434 (97.1) | ||
| Multiple | 524 (88.8) | 377 (86.9) | 1.2 (0.8, 1.8) | 0.3436 |
| Bilateral | 502 (85.1) | 357 (82.3) | 1.3 (0.9, 1.8) | 0.1585 |
| Lesion >3 cm | 212 (35.9) | 130 (30.0) | 1.4 (1.1, 1.9) | 0.0119 |
| Growing | 135 (22.9) | 81 (18.7) | 1.4 (1.0, 1.9) | 0.0439 |
| Renal angiomyolipoma signs and symptomsb,c | ||||
| None | 466 (79.0) | 374 (86.2) | 0.6 (0.4, 0.8) | 0.0031 |
| Elevated blood pressure | 31 (5.3) | 27 (6.2) | 0.8 (0.5, 1.4) | 0.5083 |
| Haematuria (blood in urine) | 29 (4.9) | 14 (3.2) | 1.6 (0.8, 3.0) | 0.1829 |
| Hemorrhage | 41 (6.9) | 14 (3.2) | 2.2 (1.2, 4.2) | 0.0090 |
| Impaired renal function | 27 (4.6) | 12 (2.8) | 1.7 (0.8, 3.4) | 0.1345 |
| Pain | 50 (8.5) | 13 (3.0) | 3.0 (1.6, 5.6) | 0.0003 |
| Others | 22 (3.7) | 8 (1.8) | 2.1 (0.9, 4.7) | 0.0771 |
| Treatment received for renal angiomyolipomad | 203 (33.0) | 112 (25.1) | ||
| mTOR inhibitor | 95 (46.8) | 49 (43.8) | 1.1 (0.7, 1.78) | 0.6395 |
| Embolization | 84 (41.4) | 57 (50.9) | 0.7 (0.4, 1.1) | 0.0894 |
| Nephrectomy | 47 (23.2) | 16 (14.3) | 1.8 (1.0, 3.4) | 0.0629 |
| Resection | 16 (7.9) | 5 (4.5) | 1.8 (0.6, 5.1) | 0.2503 |
| Dialysis | 3 (1.5) | 1 (0.9) | 1.7 (0.2, 16.1) | 0.6618 |
| Other | 10 (4.9) | 3 (2.7) | 1.9 (0.5, 6.9) | 0.3428 |
CI, confidence interval; mTOR, mammalian target of rapamycin.
Values are expressed as n (%) unless otherwise specified.
a
Percentages calculated based on denominator of patients with history of renal angiomyolipoma.
b
Percentages calculated from number of patients with renal angiomyolipoma ongoing during the study.
c
The numbers include patients who experienced more than one symptom simultaneously.
d
Treatment received as monotherapy or polytherapy.